Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength

CNBC Markets

·

Original Report

↗ CNBC Markets

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.